REGNREGENERON PHARMACEUTICALS, INC.
Pharmaceutical Preparations
- Revenue
- $14.3B
- 1.0% YoY
- Operating margin
- 24.9%
- 11% YoY
- EBITDA
- $4.1B
- 7.9% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -0.4×
- −$1.7B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear111% of net incomeCash flow under 80% of net income
- Dilutive SBCClear7% of revenueOver 10% of revenue
- Payouts exceed cash flowClear77% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B | 1.0% |
| Operating income | $8.9B | $4.7B | $4.0B | $4.0B | $3.6B | 10% |
| Net income | $8.1B | $4.3B | $4.0B | $4.4B | $4.5B | 2.1% |
| Operating cash flow | $7.1B | $5.0B | $4.6B | $4.4B | $5.0B | 13% |
| Capex | $552M | $590M | $719M | $756M | $898M | 19% |
| Stock-based comp | $602M | $725M | $885M | $983M | $994M | 1.1% |
| Buybacks | $1.6B | $2.1B | $2.2B | $2.6B | $3.4B | 32% |
| Dividends | — | — | $0 | $0 | $370M |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $3M · 27
- Net
- −$3M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $7M | $39M | 160 | 201 |
| FY2024 | $7M | −$38M | 147 | 156 |
| FY2023 | $8M | $141M | 182 | 144 |
| FY2022 | $7M | $99M | 149 | 139 |
| FY2021 | $6M | $124M | 131 | 124 |